2-cyclopropyl-3-[6-(2-methoxyethoxy)-3-pyridinyl]-6-methyl-8-(4-morpholinyl)-imidazo[1,2-b]pyridazine | 1298031-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-cyclopropyl-3-[6-(2-methoxyethoxy)-3-pyridinyl]-6-methyl-8-(4-morpholinyl)-imidazo[1,2-b]pyridazine
• 英文别名: 4-[2-Cyclopropyl-3-[6-(2-methoxyethoxy)pyridin-3-yl]-6-methylimidazo[1,2-b]pyridazin-8-yl]morpholine
• CAS: 1298031-07-8
• 化学式: C₂₂H₂₇N₅O₃
• 分子量: 409.488
• InChiKey: CQWJNYOAPYJJMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
  申请人：Pastor-Fernández Joaquin

  公开号：US20110269752A1

  公开（公告）日：2011-11-03

  The present invention relates to novel imidazo[1,2- b ]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-b]吡啶嗪衍生物，其为磷酸二酯酶10（PDE10）的抑制剂，并且适用于治疗或预防涉及PDE10酶的神经、精神和代谢紊乱。该发明还涉及包含这种化合物的药物组合物，用于制备这种化合物和组合物的方法，以及利用这种化合物或药物组合物预防或治疗神经、精神和代谢紊乱和疾病。
• US8716282B2
  申请人：——

  公开号：US8716282B2

  公开（公告）日：2014-05-06
• [EN] IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-B]PYRIDAZINE ET LEUR UTILISATION COMME INHIBITEURS DE PDE10
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011051342A1

  公开（公告）日：2011-05-05

  The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.